Author: Alison James

Coulter Partners secures Chief Scientific Officer for OxStem

Coulter Partners was very pleased to partner once again with OxStem Limited to secure the appointment of Dr. Ian Churcher to the role of Chief Scientific Officer.
Ian Churcher has 22 years’ experience in pharmaceutical R&D obtained in positions of increasing seniority in international companies including Merck Sharp & Dohme (Merck), GlaxoSmithKline (GSK) and BenevolentAI

SHOWCASE: Medical Technology 2020

Historically a siloed industry focussed on hardware and equipment, medtech has evolved into a complex landscape encompassing everything from artificial intelligence-enabled imaging and wearable devices to implantable bioelectronics and surgical robots. Convergence of technologies, the shift from hardware to software and the rate of digital disruption along with increased patient empowerment, diversification and the rise in consumer-technology, are fast changing traditional models. With a geriatric population predicted by the WHO to reach 1.5 billion by 2050¹ and chronic and lifestyle diseases increasing as a result, the demand for medical devices and advanced technology continues to grow year-on-year. 2018 saw medtech’s third consecutive year of growth with collective revenues increasing by 7% to US$407.2 billion². Investor interest in the sector remains keen and the arrival of non-traditional entrants continues to drive a highly competitive landscape and strong M&A activity. Neha Rajdev here presents some of the talent and leadership opportunities ahead for medtech and the work that Coulter Partners is doing in this sector, as we fast-forward to the 2020s…

CEO PERSPECTIVE: Charles De Rohan, Chief Executive Officer, Binding Site

Founded by researchers at the University of Birmingham, Binding Site provides specialist diagnostic products to clinicians and laboratory professionals worldwide, delivering innovative medical solutions that significantly improve the diagnosis and management of blood cancers and immune system disorders. With extensive expertise in antibody specificity technology, Binding Site has been researching, developing, manufacturing and distributing specialist immunodiagnostic assays and instrumentation for over 30 years. The UK head office in Birmingham houses all product development, manufacturing, global distribution and marketing, while worldwide customer support is provided by a further 10 offices in the US and Europe.

Coulter Partners has worked with Binding Site over many years and helped secure many senior appointments across the business that include Commercial Director, Head of Marketing, Head of R&D, Head of QA/RA, Operations Director, Head of Prototyping, UK & Ireland General Manager and Quality Engineering Manager.

Coulter:Pulse recently spoke to Charles De Rohan, CEO of Binding Site about their plans and talent challenges…

INSIGHT: Medtech Specialists in Conversation

Medtech across Diagnostics, Devices, Digital and Life Science Tools is a key focus of Coulter Partners’ executive search work and their fastest growing Life Sciences segment. Client Partner, Penny Sadler and Managing Partner, Nick Green bring a wealth of experience in medtech executive search and here discuss some of the principal drivers and talent implications across the space. “We have never seen a more exciting medtech landscape, with a truly global innovation ecosystem generating growth in all corners of the planet. Our Asia-Pacific team is seeing companies beginning to scale their local markets into EMEA and the US and conversely our clients in established medtech markets are looking to us to help them access the emerging wealth and health demands in huge markets like China, India, Japan and South East Asia,” concludes Penny…

Coulter Partners opens Brussels office and makes six strategic appointments

We are delighted to announce the opening of a new office in the Belgian capital and six key appointments. Penny Sadler strengthens the company’s rapidly growing Med Tech expertise as Client Partner in Brussels, while Dr Nanna Soni (PhD DIC) is appointed Director in London to the R&D centre of expertise. The Paris office expands with the appointments of Nicolas Leray as Executive Director and Mélanie Blanchard as Senior Consultant. Gwen Gioia joins as Senior Consultant in Short Hills, New Jersey and Heike Haertling is appointed Senior Consultant in Frankfurt.

Coulter Partners secures Chief Scientific Officer for Azitra

Coulter Partners was delighted to partner recently with Azitra Inc. and secure the appointment of Mark Sampson, Ph.D. as their Chief Scientific Officer. Azitra is a clinical-stage medical dermatology company addressing severe skin conditions by harnessing the microbiome and has just announced that it has closed a $14 million Series A financing, led by KdT Ventures in conjunction with existing investor Bios Partners.

Coulter Partners secures Non-Executive Director for Nanoform

Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome Mads Laustsen to the Nanoform board. Mads is an exceptional entrepreneur with vast experience in the provision of GMP facilities and infrastructures. His outstanding experience will be incredibly valuable as we expand our manufacturing capacity and I thank the highly professional team at Coulter Partners for helping us once more to achieve such a quality appointment.”

Coulter Partners expands to Asia-Pacific with new offices in Sydney and Singapore

We are delighted to announce the opening of new offices in Sydney and Singapore and three key appointments. Steven Johnson joins as Executive Director in Sydney, while Martin Grindrod is appointed Director in Singapore. In London, Rob Sansom joins as Director to consolidate the international Commercial Pharmaceutical team, working alongside Gert Andersen, Dr Christoph Themel, Mark Sharp and recently appointed Hugues Petit.